CD8A and neoplasm: Consequently, the ratios of CD4+ and CD8+ T cells to MDSCs or TAMs were increased following Doxil® treatment, which is anticipated to contribute, at least in part, to the increased antitumor efficacy of Doxil® in the tumor-bearing mice compared to the free drug (Figure 1A).